Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 12 (June 15), 2004: pp. 2438-2444
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.08.194

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diener-West, M.
Right arrow Articles by Thoma, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diener-West, M.
Right arrow Articles by Thoma, J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report 23

Marie Diener-West, Sandra M. Reynolds, Donna J. Agugliaro, Robert Caldwell, Kristi Cumming, John D. Earle, Donna L. Green, Barbara S. Hawkins, James Hayman, Ishmael Jaiyesimi, John M. Kirkwood, Wui-Jin Koh, Dennis M. Robertson, John M. Shaw, Jonni Thoma

From the The Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD; Midwest Eye Institute, Indianapolis, IN; Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA; Mayo Clinic, Jacksonville, FL; Retina-Vitreous Consultants; University of Pittsburgh, Pittsburgh, PA; University of Michigan, Ann Arbor; Associated Retinal Consultants; Beaumont Cancer Center, Royal Oak, MI; University of Washington, Seattle, WA; Mayo Clinic, Rochester, MN; Northwestern University, Chicago, IL; and The University of Virginia, Charlottesville, VA

Address reprint requests to Marie Diener-West, PhD, COMS Coordinating Center, Wilmer Clinical Trials and Biometry, 550 N Broadway, Floor 9, Baltimore, MD 21205; e-mail: mdiener{at}jhsph.edu

PURPOSE: To describe the predictive value of liver function tests (LFTs), chest x-ray, and diagnostic imaging for detecting melanoma metastasis during routine follow-up after treatment for choroidal melanoma.

MATERIALS AND METHODS: Prospective longitudinal follow-up of patients enrolled onto two randomized trials was conducted by the Collaborative Ocular Melanoma Study (COMS) Group. Baseline and annual or semiannual systemic and laboratory evaluations were performed according to a standard protocol for 2,320 patients enrolled on the COMS.

RESULTS: COMS patients were screened annually for metastasis and new cancers using LFTs (alkaline phosphatase, AST, ALT, or bilirubin). Elevated findings (1.5 to 2 times upper limit of normal) on LFT prompted a diagnostic or imaging test to confirm or rule out cancer recurrence. Of 714 patients with clinical reports of metastasis, 675 patients died. Of these 675 patients, all but four had either histopathologically confirmed or clinically suspected metastatic melanoma present at the time of death. Among all patients, the 5-year cumulative diagnosis rate of metastatic melanoma was 24% (95% CI, 22% to 27%). Based on all patients with reported metastasis, the sensitivity, specificity, positive predictive value and negative predictive value associated with at least one abnormal LFT before first diagnosis of metastasis at any site was 14.7%, 92.3%, 45.7% and 71.0%, respectively.

CONCLUSION: Use of LFTs results followed by diagnostic tests has high specificity and predictive values but low sensitivity. Better tests are needed to identify earlier metastatic disease associated with choroidal melanoma.

Supported by the National Eye Institute and the National Cancer Institute through cooperative agreements EY06253, EY06257, EY06258, EY06259, EY06020, EY06264, EY06265, EY06266, EY06268, EY06269, EY06270, EY06274, EY06275, EY06276, EY06279, EY06280, EY06282, EY06283, EY06284, EY06287, EY06288, EY06289, EY06291, EY06839, EY06843, EY06844, EY06848, EY06858, EY06899 with the National Institutes of Health, Bethesda, MD.

A complete list of the COMS Group members as of September 30, 2000, is in Arch Ophthalmol 119:961–965, 2001.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch OphthalmolHome page
C. L. Shields, M. Furuta, A. Thangappan, S. Nagori, A. Mashayekhi, D. R. Lally, C. C. Kelly, D. S. Rudich, A. V. Nagori, O. A. Wakade, et al.
Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes
Arch Ophthalmol, August 1, 2009; 127(8): 989 - 998.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
V. Barak, S. Frenkel, K. Valyi-Nagy, L. Leach, M. A. Apushkin, A. Y. Lin, I. Kalickman, N. A. Baumann, J. Pe'er, A. J. Maniotis, et al.
Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4399 - 4402.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
E. S. Gragoudas
Proton Beam Irradiation of Uveal Melanomas: The First 30 Years The Weisenfeld Lecture
Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4666 - 4673.
[Full Text] [PDF]


Home page
IOVSHome page
P. L. Blanco, J. C. A. Marshall, E. Antecka, S. A. Callejo, J. P. Souza Filho, V. Saraiva, and M. N. Burnier Jr
Characterization of Ocular and Metastatic Uveal Melanoma in an Animal Model
Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4376 - 4382.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
Collaborative Ocular Melanoma Study Group*
Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No. 26
Arch Ophthalmol, December 1, 2005; 123(12): 1639 - 1643.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Rietschel, K. S. Panageas, C. Hanlon, A. Patel, D. H. Abramson, and P. B. Chapman
Variates of Survival in Metastatic Uveal Melanoma
J. Clin. Oncol., November 1, 2005; 23(31): 8076 - 8080.
[Abstract] [Full Text] [PDF]


Home page
Br J OphthalmolHome page
P T Finger, M Kurli, S Reddy, L B Tena, and A C Pavlick
Whole body PET/CT for initial staging of choroidal melanoma
Br J Ophthalmol, October 1, 2005; 89(10): 1270 - 1274.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online